New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
13:25 EDTABT, ABT, DXCM, DXCM, JNJ, JNJ, MDT, MDT, PODD, PODD, TNDM, TNDMLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy provides a preview of the upcoming American Diabetes Association's 74th Scientific Sessions on an Analyst/Industry conference call. Relevant companies ABT, DXCM, JNJ, MDT, PODD and TNDM may be discussed on the Analyst/Industry conference call to be held on June 12 at 2 pm.
News For ABT;DXCM;JNJ;MDT;PODD;TNDM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 18, 2014
07:17 EDTMDTMedtronic reports Q2 EPS 96c, consensus 96c
Subscribe for More Information
November 17, 2014
15:16 EDTMDTNotable companies reporting before tomorrow's open
Subscribe for More Information
08:57 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 28, December is at 21, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
08:16 EDTABTZoetis to purchase assets of Abbott Animal Health for about $255M
Subscribe for More Information
08:15 EDTABTZoetis to purchase assets of Abbott Animal Health for about $255M
07:16 EDTJNJMilken Institute--Faster Cures to hold a conference
Subscribe for More Information
November 16, 2014
14:08 EDTMDTDaVita announces collaboration with Medtronic
DaVita Kidney Care, a division of DaVita HealthCare Partners (DVA) and leading provider of kidney care services, announced a collaboration with Medtronic (MDT) to better understand cardiovascular health in end stage renal disease, ESRD patients. The collaboration will focus on developing a pilot program using Medtronic's Reveal LINQ Insertable Cardiac Monitoring system to identify cardiac arrhythmias in patients receiving dialysis. "Medtronic recently announced data at the American Society of Nephrology meeting that showed a higher incidence of arrhythmias in patients receiving hemodialysis," said Ven Manda, vice president, Renal Care Solutions at Medtronic. "We are pleased to pursue this collaboration with DaVita to monitor more patients and gather additional data that will further our understanding of the relationship between dialysis and cardiac events in ESRD patients." "Given the high incidence rate of cardiovascular disease and events in ESRD patients, we believe that by collaborating with Medtronic, we can gain knowledge to help improve the lives of ESRD patients," said Mahesh Krishnan, vice president for clinical innovation and public policy for DaVita HealthCare Partners. "Through the collaboration we expect to utilize innovative monitoring technology and data from our DaVita Kidney Care information systems across the country. This effort is poised to improve the lives of patients by proactively detecting and preventing cardiac complications."
November 14, 2014
16:21 EDTJNJOn The Fly: Closing Wrap
Subscribe for More Information
14:53 EDTJNJCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:43 EDTMDTMedtronic readying $10B bond sale for Covidien deal, WSJ reports
Subscribe for More Information
11:50 EDTMDTMedtronic readying $10B bond sale for Covidien deal, Dow reports
Subscribe for More Information
November 13, 2014
16:35 EDTMDTMedtronic study reveals heart rhythm disorders in patients with ESRD
Subscribe for More Information
16:28 EDTJNJGeron announces global strategic collaboration with Janssen Biotech
Geron (GERN) announced that the company has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, a Johnson & Johnson (JNJ) company, to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Imetelstat is a modified oligonucleotide that is currently in early phase clinical development for myelofibrosis, or MF, and may have activity in other hematologic myeloid malignancies such as myelodysplastic syndrome, or MDS, and acute myelogenous leukemia, or AML. Under the terms of the agreement, Geron will receive an initial payment of $35M due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900M for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities. All sales will be booked by Janssen.
14:50 EDTMDTLonestar Capital to shut down by mid-2015, WSJ reports
Subscribe for More Information
14:45 EDTMDTLonestar capital to shut down, DJ reports
Subscribe for More Information
13:27 EDTMDTMedtronic likely to continue to make new highs, Barron's says
Subscribe for More Information
11:54 EDTJNJJanssen announces FDA approved sNDA for INVEGA SUSTENNA
Subscribe for More Information
10:44 EDTJNJMallinckrodt news on generic Concerta positive for Actavis, says BMO Capital
Subscribe for More Information
November 12, 2014
07:23 EDTMDTMedtronic volatility elevated into Q2 and outlook
Medtronic November call option implied volatility is at 23, December is at 20, January is at 19, February is at 18; compared to its 26-week average of 19 according to Track Data, suggesting large near term price movement into the expected release of Q2 results on November 18.
November 11, 2014
07:24 EDTMDTMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use